Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation

ClinicalTrials.gov ID: NCT05652205

Public ClinicalTrials.gov record NCT05652205. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 7, 2026, 1:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Safety and Efficacy Study of Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation (FC) With a 24-week Open-label Treatment Extension

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Functional constipation (FC) is a common healthcare problem in children of all ages, potentially due to genetic predisposition, inadequate fiber and fluid intake, and immobility. Currently, there are no pharmacological therapies approved for the treatment of FC. This study will assess adverse events and change in disease activity with linaclotide therapy in participants with FC. Linaclotide is an approved drug being developed for the treatment of FC in pediatric patients, ages 2 to 5, who meet modified Rome IV criteria for childhood FC. In Part 1 of this study, participants are placed in 1 of 2 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 2 chance that participants will be assigned to placebo. All participants in Part 2 will receive linaclotide. Approximately 116 participants aged 2 to 5 years with FC will be enrolled in this study at around 45 sites worldwide. Participants will receive daily doses of oral Linaclotide capsules or matching placebo for 12 weeks in Part 1 of the study. In Part 2, the open label long-term safety extension, participants with FC who completed study intervention in Part 1 of Study M21-572 or the Phase 2 Study LIN-MD-67 will receive linaclotide for 24 weeks. There may be higher treatment burden for participants in this trial compared to their standard of care (due to study procedures). Participants will attend visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Study identification

NCT ID
NCT05652205
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
AbbVie
Industry
Enrollment
123 participants

Conditions and interventions

Eligibility (public fields only)

Age range
2 Years to 5 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 28, 2022
Primary completion
Sep 1, 2025
Completion
Sep 1, 2025
Last update posted
May 13, 2026

2022 – 2025

United States locations

U.S. sites
38
U.S. states
22
U.S. cities
36
Facility City State ZIP Site status
G & L Research, LLC /ID# 250658 Foley Alabama 36535
Velocity Clinical Research - Phoenix /ID# 266280 Phoenix Arizona 85006
HealthStar Research of Hot Springs PLLC /ID# 249481 Hot Springs Arkansas 71913
Applied Research Center of Arkansas /ID# 249764 Little Rock Arkansas 72212-4187
Advanced Research Center /ID# 249412 Anaheim California 92805
Kindred Medical Institute - Corona /ID# 249485 Corona California 92879-3104
Medical Ctr for Clin Research /ID# 254386 San Diego California 92108
Prohealth Research Center /ID# 249420 Doral Florida 33166
KIDZ Medical Services - Hollywood /ID# 250823 Hollywood Florida 33021-6030
Nemours Children's Health System /ID# 250881 Jacksonville Florida 32207
Kissimmee Clinical Research /ID# 252206 Kissimmee Florida 34741
South Miami Medical & Research Group Inc. /ID# 249418 Miami Florida 33155
Valencia Medical & Research Center /ID# 250452 Miami Florida 33165
Palmetto Professional Research /ID# 250875 Miami Florida 33172
South Florida Research Ph I-IV /ID# 252350 Miami Springs Florida 33166-7225
Velocity Clinical Research Macon /ID# 266516 Macon Georgia 31210-6583
Rophe Adult & Pediatric Medicine /ID# 250663 Union City Georgia 30291
Michael W. Simon, MD, PSC /ID# 250664 Lexington Kentucky 40517
Velocity Clinical Research - Lafayette /ID# 266751 Lafayette Louisiana 70508
Frederick County Pediatrics /ID# 249483 New Market Maryland 21774-6154
Michigan Center of Medical Research /ID# 251088 Farmington Hills Michigan 48334
MNGI Digestive Health, P. A. /ID# 249676 Minneapolis Minnesota 55413-2195
Velocity Clinical Research- Hastings Nebraska /ID# 252132 Hastings Nebraska 68901-2640
Rutgers New Jersey Medical School Campus, Doctors Office Center /ID# 250876 Newark New Jersey 07103-2425
Univ NC Chapel Hill /ID# 252044 Chapel Hill North Carolina 27514-4220
UH Cleveland Medical Center /ID# 250893 Cleveland Ohio 44106
IPS Research Company /ID# 250822 Oklahoma City Oklahoma 73106
Frontier Clinical Research, LLC - Scottdale /ID# 250656 Scottdale Pennsylvania 15683
Frontier Clinical Research - Smithfield /ID# 250657 Smithfield Pennsylvania 15478
Coastal Pediatric Research - West Ashley B /ID# 249413 Charleston South Carolina 29414
Tribe Clinical Research LLC /ID# 255656 Greenville South Carolina 29607-4021
Coastal Pediatric Research - Summerville /ID# 249423 Summerville South Carolina 29486
Tullahoma Pediatrics /ID# 250892 Tullahoma Tennessee 37388
Houston Clinical Research Associates /ID# 250779 Houston Texas 77090-2633
Prime Clinical Research - Mansfield - East Broad Street /ID# 266236 Mansfield Texas 76063
ClinPoint Trials /ID# 250448 Waxahachie Texas 75165-1430
Carilion Medical Center /ID# 249790 Roanoke Virginia 24014
Frontier Clinical Research - Kingwood /ID# 251154 Kingwood West Virginia 26537-9797

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05652205, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 13, 2026 · Synced Sep 7, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05652205 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →